文献速递关节外科创伤骨科

慢性抗凝患者初次全髋置换术后使用选择性COX-2抑制剂的安全性

The Safety of Postoperative Selective Cyclooxygenase-2 Inhibitors in Chronically Anticoagulated Patients Undergoing Primary Total Hip Arthroplasty.
PubMed 文献 · J Arthroplasty · 2026-09-21

基于全国数据库的观察性研究,纳入2015至2025年接受初次全髋关节置换术的慢性抗凝患者,按术后是否使用选择性COX-2抑制剂分层并经倾向评分匹配。结果显示COX-2抑制剂未增加输血、再入院、再手术、深静脉血栓、急性肾损伤等风险,且与更低的累积阿片类药物使用相关。

要点

  • 慢性抗凝患者初次全髋置换术后使用选择性COX-2抑制剂未增加输血或再入院风险。
  • COX-2抑制剂组在30、90、180天累积阿片类药物使用均显著低于未使用组。
  • 肺栓塞在COX-2抑制剂组方向性更低,180天时达到名义显著性(RR 0.46,P=0.012)。

核心结论

  • 在慢性抗凝患者初次全髋关节置换术后,使用选择性COX-2抑制剂与出血、再入院、肾脏或手术并发症增加无关,且与更低的累积术后阿片类药物使用相关。

研究设计与样本

  • 利用全国数据库识别2015至2025年间接受初次全髋关节置换术的慢性抗凝患者,按术后是否使用选择性COX-2抑制剂(塞来昔布或美洛昔康)分层。
  • 采用倾向评分匹配平衡组间人口学和临床特征,匹配协变量包括术前贫血和急性肾损伤病史。

主要发现

  • COX-2抑制剂使用在任何时间点均未与输血、住院再入院、再手术、假体周围脱位、深静脉血栓、急性肾损伤或急诊就诊率升高相关(所有P>0.05)。
  • 肺栓塞在COX-2抑制剂组方向性更低,180天时达到名义显著性(风险比[RR] 0.46,P=0.012)。
  • COX-2抑制剂组累积阿片类药物使用在30天(9.84% vs 17.35%;RR 0.567,P<0.001)、90天(11.89% vs 18.78%;RR 0.633,P<0.001)和180天(15.33% vs 21.88%;RR 0.701,P<0.001)均低于未使用组。

关键数值与推荐

  • 主要结局为术后累积30、90和180天的输血和再入院。
  • 次要结局包括再手术、假体周围脱位、深静脉血栓、肺栓塞、急性肾损伤、急诊利用和至180天的累积阿片类药物使用。

临床怎么用

  • 这些观察性发现支持在慢性抗凝患者初次全髋关节置换术后的多模式镇痛中谨慎使用COX-2抑制剂。

局限性

  • 原文指出这些为观察性发现,需要未来前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Nonsteroidal anti-inflammatory drugs, particularly selective cyclooxygenase-2 (COX-2) inhibitors, are foundational to multimodal pain management following primary total hip arthroplasty (THA), but concerns regarding bleeding often limit their use in patients receiving chronic anticoagulation. While data support COX-2 inhibitor safety following total knee arthroplasty in this population, THA-specific evidence remains limited. METHODS: Utilizing a national database, patients undergoing primary THA on chronic anticoagulation between 2015 and 2025 were identified and stratified by postoperative exposure to selective COX-2 inhibitors (celecoxib or meloxicam). Propensity-score matching, which included preoperative anemia and history of acute kidney injury as covariates, balanced demographic and clinical characteristics between groups. The primary outcomes were blood transfusion and readmission at cumulative 30, 90, and 180 days postoperatively. Secondary outcomes included reoperation, periprosthetic dislocation, deep vein thrombosis, pulmonary embolism, acute kidney injury, emergency department utilization, and cumulative opioid use through 180 days. RESULTS: The COX-2 inhibitor use was not associated with elevated rates of transfusion, inpatient readmission, reoperation, periprosthetic dislocation, deep vein thrombosis, acute kidney injury, or emergency department utilization at any time point (all P > 0.05). Pulmonary embolism was directionally lower in the COX-2 cohort, reaching nominal significance at 180 days (risk ratio [RR] 0.46, P = 0.012). The COX-2 inhibitor recipients demonstrated lower cumulative opioid use at 30 days (9.84 versus 17.35%; RR: 0.567, P < 0.001), 90 days (11.89 versus 18.78%; RR: 0.633, P < 0.001), and 180 days (15.33 versus 21.88%; RR: 0.701, P < 0.001) compared with patients not receiving COX-2 inhibitors. CONCLUSIONS: In chronically anticoagulated patients undergoing primary THA, postoperative COX-2 inhibitor use was not associated with increased bleeding, readmission, renal, or surgical complications and was associated with lower cumulative postoperative opioid utilization. These observational findings support cautious COX-2 inhibitor use within multimodal analgesia in this population; however, future prospective studies are warranted to validate these findings.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Tummala S, Valencia A, Chen AF, et al. The Safety of Postoperative Selective Cyclooxygenase-2 Inhibitors in Chronically Anticoagulated Patients Undergoing Primary Total Hip Arthroplasty. J Arthroplasty. 2026. PMID: 42767534. doi:10.1016/j.arth.2026.09.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。